US2003233116A1PendingUtilityA1

Implantable intraluminal device

Assignee: SOD CONSEILS RECH APPLICPriority: Jun 4, 1998Filed: Jun 18, 2003Published: Dec 18, 2003
Est. expiryJun 4, 2018(expired)· nominal 20-yr term from priority
A61F 2/02A61F 2002/065A61F 2/86A61F 2002/068A61F 2/01
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A device implantable in the vascular ducts. The device includes an elongated intraluminal element that occupies a section of the vascular lumen so as to increase the speed at the vascular wall at the level of the element without decreasing the blood flow and without exerting any substantial mechanical action on the vascular wall, the element also includes a fixing device in the vascular lumen.

Claims

exact text as granted — not AI-modified
1 . A device for implantation in the vasculature, comprising: 
 an elongate intraluminal element implantable in a portion of a vascular lumen, in which the vascular wall has undergone angioplasty restoring the lumen, said elongate intraluminal element occupying a volume of said vascular lumen in said portion without reducing the blood flow through said vascular lumen and without exerting appreciable mechanical action on a vascular wall, said element being associated with a means of fixing into the vascular lumen.    
     
     
         2 . The device as claimed in  claim 1  comprising a solid element ( 8 ,  17 ,  21 ,  29 ) of elongate shape, with a smooth surface, and with constant diameter and cross section.  
     
     
         3 . The device as claimed in  claim 1  having a proximal end or anchoring zone ( 12 ,  13 ,  18 ,  19 ,  23 ,  31 ) that can be fixed to or through the wall of the vessel, followed by a rod and by a distal end which is free in the blood stream so that only the anchoring zone is in permanent contact with the tissues of the vessel.  
     
     
         4 . The device as claimed in  claim 1 , with a diameter of 0.5 to 2 mm and a length of 0.5 to 15 cm.  
     
     
         5 . The device as claimed in  claim 1 , with a cross section of between 5 and 50% of the cross section of the vessel in which it is implanted.  
     
     
         6 . The device as claimed in  claim 1 , with a cross section of between 10 and 20% of the cross section of the vessel in which it is implanted.  
     
     
         7 . The device as claimed in one of claims  1 , in which said fixing means comprises an anchoring zone made of a material which, when the device is placed in the vascular lumen, allows a change in shape leading to at least two points of contact with the vascular wall.  
     
     
         8 . The device as claimed in  claim 1 , in which said fixing means ( 23 ,  31 ) comprises an anchoring zone allowing direct implantation in the wall of the vessel.  
     
     
         9 . The device as claimed in  claim 8 , characterized in that said anchoring zone is made of a material allowing it to deform when the device is placed in the vascular lumen.  
     
     
         10 . The device as claimed in  claim 7 , characterized in that it is deformable into a roughly straight position so that it can be fitted using a needle or a catheter.  
     
     
         11 . The device as claimed in  claim 1 , in which said fixing means are arranged to allow said device to be withdrawn.  
     
     
         12 . The device as claimed in  claim 1 , made of stainless steel, alloy or plastic.  
     
     
         13 . The device as claimed in  claim 1 , made of nylon, polysulfone, of Teflon or of silicone.  
     
     
         14 . The device as claimed in  claim 1 , made of PLGA.  
     
     
         15 . The device as claimed in  claim 1 , the surface of which is covered with a coating.  
     
     
         16 . The device as claimed in  claim 15 , in which said coating is made of hyaluronic acid, collagen, PEG, glycol, hydrogel or PLGA.  
     
     
         17 . The device as claimed in  claim 1 , containing a releaseable active principle.  
     
     
         18 . The device as claimed in  claim 17  in which the active principle is Lanreotide, hydrocortisone, a glucocorticoid or a cytostatic.  
     
     
         19 . The device as claimed in  claim 12 , the surface of which is hydrophilic, silicone coated or surfaced.  
     
     
         20 . The device as claimed in  claim 1 , produced by melt extrusion or co-extrusion or by die-forming and drawing.

Join the waitlist — get patent alerts

Track US2003233116A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.